Skip to main content
The FDA has approved a new oral tyrosine kinase inhibitor with potent, reversible, selective dual inhibition of epidermal growth factor receptor (EGFR) and ErbB2 kinases.

Lapatinib Tablets (Tykerb®)

April 30, 2007

The FDA has approved a new oral tyrosine kinase inhibitor with potent, reversible, selective dual inhibition of epidermal growth factor receptor (EGFR) and ErbB2 kinases.